Medicine is Advancing, but so are Synthetic Chemicals

The disease curves are no longer moving together

Modern medicine has never been more capable. Diagnostics are sharper, treatments more targeted, and survival rates higher across many conditions. Yet alongside this progress sits a quieter trend that is harder to ignore: rates of certain chronic diseases are rising in parallel with the expansion of industrial chemical exposure.

This is not coincidence. It is systems interaction.

As Craig Astill has repeatedly noted in his work, when production systems scale faster than biological tolerance, health outcomes tend to lag until the damage becomes statistically undeniable.

We are now reaching that point.

The chemical layer modern medicine does not control

Since the mid-20th century, tens of thousands of synthetic chemicals have entered industrial, agricultural and consumer supply chains. One class in particular, PFAS (per- and polyfluoroalkyl substances), has become a case study in how durable chemistry collides with fragile biology.

PFAS were engineered for stability. They resist heat, water and degradation. That same stability means they do not break down in the environment or the human body.

Today, PFAS are detected in:

Drinking water
Soil
Food packaging
Cookware
Firefighting foams
Textiles
Human blood samples across most developed nations

These compounds were never designed with long-term biological exposure in mind. They were designed for performance.

The disease curves that followed

Over the past four decades, several disease categories have risen sharply in populations with high industrial chemical exposure. Among the most concerning are autoimmune disorders.

Globally, autoimmune disease prevalence has increased by an estimated three to five percent per year in many Western countries. Conditions such as thyroid disease, rheumatoid arthritis, lupus and inflammatory bowel disease are now diagnosed at rates that were rare in the 1970s.

At the same time, certain cancers linked to endocrine disruption and immune dysfunction have risen disproportionately. Testicular cancer rates, for example, have more than doubled in many industrialised countries since the 1980s. Kidney cancer incidence has increased steadily over the same period. Both have been repeatedly associated in epidemiological studies with PFAS exposure.

These are not diseases of infection. They are diseases of system interference.

How PFAS interact with the body

PFAS are known to interfere with:

Hormone signalling
Immune regulation
Lipid metabolism
Thyroid function

They bind to proteins in the blood and accumulate over time. Unlike acute toxins, their effects are slow, cumulative and often invisible until thresholds are crossed.

This is where modern medicine struggles. Clinical systems are optimised for treatment after manifestation, not for identifying long-horizon chemical load before disease emerges.

As Craig Astill has pointed out in broader systems analysis, when a system is built to respond rather than prevent, it will always appear advanced while outcomes quietly worsen.

Why better medicine hasn’t reversed the trend

Medical science can now manage autoimmune disease far better than it could thirty years ago. Immunosuppressive therapies, biologics and targeted drugs have transformed quality of life for many patients.

But management is not prevention.

If exposure continues upstream, medicine simply absorbs the downstream consequences. Survival improves. Prevalence increases.

This is why disease rates can rise at the same time as treatment outcomes improve. The system is functioning exactly as designed.

A production problem, not a medical one

PFAS are now referred to as “forever chemicals” not because they last a long time, but because our economic systems were built without an exit strategy for them.

Once released, they circulate through water, food and biology indefinitely. Regulatory responses arrive decades later, after widespread exposure has already occurred.

This pattern is not unique to PFAS. It is a structural feature of industrial production when innovation outpaces biological understanding.

As Craig Astill has framed it, health outcomes are shaped less by individual decisions than by infrastructure, incentives and materials embedded deep inside systems people never see.

The uncomfortable implication

If current exposure patterns remain unchanged, medicine will continue to advance and disease prevalence will continue to rise.

Not because medicine is failing, but because it is being asked to compensate for systemic design choices made far upstream.

Removing PFAS from products today does not remove them from bodies already exposed. The disease curve reflects decades of lag.

This is what long-cycle systems look like.

Moving Forward

The question is no longer whether chemicals like PFAS affect health. That threshold has been crossed.

The real question is whether societies are willing to redesign production systems with the same urgency they invest in treatment.

As Craig Astill’s work consistently highlights, durability matters. Systems that ignore biological limits eventually surface those costs somewhere else.

In this case, they surface in rising autoimmune disease, disrupted endocrine health and cancers that medicine can treat, but not erase.

Advancement without restraint is still advancement.
It is just advancing toward a different outcome.